Acute inhibition of nitric oxide synthase (NOS) has been demonstrated to reduce the anesthetic requirements of volatile anesthetics. Recent data suggest that not only volatile but also intravenous anesthetic agents interact with nitric oxide (NO) metabolism. The aim of this study was to examine the effect of NOS inhibition by nitroG-L-arginine-methyl-ester (L-NAME) on the anesthetic action of the intravenous anesthetics thiopental, propofol, and ketamine.


The anesthetic potencies of thiopental, propofol, and ketamine were determined in Xenopus laevis tadpoles in the absence and presence of L-NAME. Anesthesia was defined as loss of righting reflex for 5 s. A nonlinear logistic regression curve was fitted to the data and half-maximal effective concentrations (EC50) were calculated. A second set of experiments was performed with different concentrations of L-NAME in the presence of the previously determined the EC50 of the intravenous anesthetics.


The EC50s of the anesthetics thiopental, propofol, and ketamine were determined to be 25.5 +/- 2.0 microM, 1.9 +/- 0.1 microM, and 59.7 +/- 0.7 microM, respectively. The addition of L-NAME shifted the concentration-response curves to the left in a concentration-dependent manner. In the presence of 1 mM L-NAME, the EC50 of thiopental was reduced by 43%, the EC50 of propofol by 26%, and the EC50 of ketamine by 63%. The addition of D-NAME did not change the EC50 values of the three anesthetics. In the presence of L-arginine, the effect of L-NAME on the EC50 of thiopental was reversed. When administered by itself in a concentration range from 0.1 microM to 10 mM, L-NAME did not alter the behavior of the tadpoles.


The results of the present study show that acute inhibition of NOS by L-NAME results in reduced anesthetic requirements of the intravenous anesthetics thiopental, propofol, and ketamine. This interaction of acutely administered L-NAME and intravenous anesthetics indicates that the NO-cyclic guanosine 3',5'-monophosphate system is involved in mediating the anesthetic effect of these compounds.

Nitric oxide (NO), first described as endothelium-derived relaxing factor, was subsequently shown to play an important role as a messenger system involved in neuronal signal transduction. Instead of acting at a specific receptor located at the surface of a cell membrane, NO acts intracellularly at the enzyme guanylyl cyclase, thus increasing tissue concentrations of cyclic guano-sine 3',5'-monophosphate (cGMP). Several receptor systems, including N-methyl-D-aspartate (NMDA)-, muscarinic, and gamma-aminobutyric acid receptors and alpha2-adrenoceptors, have been shown to mediate their actions via the NO-cGMP pathway.

Nitric oxide is synthesized intracellularly by oxidation of a guanidino nitrogen atom of the amino acid L-arginine, yielding citrulline and NO. The reaction is catalyzed by the enzyme nitric oxide synthase (NOS) of which three isoforms have been described and cloned, a neuronal form, an endothelial form, and an inducible or immunologic form primarily found in macrophages. [1] Analogs of L-arginine, such as nitroG-L-arginine-methyl-ester (L-NAME), are competitive inhibitors of NOS, with no apparent specificity for one of the subtypes.

The role of NO in the regulation of consciousness is still a matter of discussion. Volatile anesthetics have been shown to affect the activity of NOS [2] and to decrease cGMP levels in the brain. [3,4] Therefore, it has been suggested that the anesthetic action of halothane is at least partly mediated by an effect on NO-cGMP metabolism. [5] However, findings on the effect of NOS inhibition remain controversial. After administration of NOS inhibitors, the minimal alveolar concentration (MAC) of halothane is either decreased or remained unchanged. [5,6] In rats chronically treated with L-NAME and in mice deficient of the neuronal NOS gene, the MAC of volatile anesthetics was not modified. [7,8]

Intravenous anesthetics such as thiopental reduce NOS activity and cerebral cGMP levels. [9,10] Although an effect of the anesthetic activity of intravenous anesthetics has been postulated, no data are available on the interaction of the NO pathway and the anesthetic action of intravenous anesthetics. If the anesthetic effect of intravenous compounds involves the NO pathway similar to inhalational anesthetics, then an inhibition of this signal transduction pathway should decrease anesthetic requirements. To test this hypothesis, the effect of L-NAME on thiopental, propofol, and ketamine requirements was determined in Xenopus laevis tadpoles. This model is well suited to determine anesthetic requirements because steady-state conditions are attained. Further, the response of tadpoles to anesthetics is similar to that of mammals, including humans. [11]


With approval of the local animal care committee, experiments were performed comparing requirements of the intravenous anesthetics thiopental, propofol, and ketamine in X. laevis tadpoles pretreated with the NOS inhibitor L-NAME with the requirements of control groups. The anesthetic potencies of the intravenous anesthetics were determined at 23 +/- 1 [degree sign] Celsius in early pre-limb-bud tadpoles about 1 cm long. Measurement of concentration-response curves was achieved by placing groups of ten tadpoles in 500-ml beakers containing aqueous oxygenated solutions of the anesthetics studied (pH, 7.0; titrated using hydrogen chloride or sodium oxide). Anesthesia was defined as loss of righting reflex, as described previously. [12,13] Briefly, after exposure to the anesthetic solution for 10 min, tadpoles were tipped with a flame-polished glass pipette. Inability of a tadpole to right itself within 5 s was scored as anesthesia. Testing was repeated every 10 min for up to 120 min. To ensure that steady-state conditions were attained, the time needed to reach a plateau in the response after exposure to several concentrations of the intravenous anesthetics was determined. A constant level of response was generally reached after 40–60 min. The half-maximal effective concentration (EC50) was measured after 90 min assuming that equilibrium conditions were achieved after this period. Concentration-response curves were determined with at least eight different concentrations of thiopental, propofol, or ketamine. The experiments were repeated three times, and the data were pooled. Thus for each anesthetic 240–280 animals were studied. Each animal was only included once per concentration and anesthetic. Determinations of anesthetic potencies in presence of L-NAME or its enantiomer D-NAME were performed in a similar manner. L-NAME or D-NAME were added in a fixed concentration of 1 mM, whereas the concentrations of thiopental, propofol, and ketamine were varied. Two similar sets of experiments were performed exposing tadpoles to L-NAME ranging from 0.1 micro Meter to 10 mM in concentration in the absence and presence of previously determined EC50values of thiopental, propofol, and ketamine. In a further experiment, the competitive nature of the NOS inhibition was evaluated by exposing tadpoles to varying concentrations of thiopental in presence of 1 mM L-NAME and 10 mM L-arginine.

After each experiment, tadpoles were placed in beakers containing tap water until full recovery of righting reflex was confirmed. No tadpole was used for more than one experiment. Concentration-response curves were analyzed according to the method of Waud [14] for quantal biologic responses. Half-maximal effective concentrations and slopes of the curves were calculated and reported as mean +/- SEM. For comparison of experiments, variances in EC50were calculated from the SEM, the sum yielding the estimated variance of the difference in the EC50. The ratio of the difference to the SEM was then referred to as a standard normal distribution. The problem of multiplicity was addressed using the Bonferroni correction to maintain a significance level of 0.05.


Exposure of X. laevis tadpoles to different concentrations of thiopental, propofol, or ketamine resulted, similar for each compound, in an increased fraction of anesthetized animals with increasing concentrations of the anesthetic. Calculated logistic concentration-response plots showed a sigmoidal curve (Figure 1). Thiopental exhibited an EC50of 25.5 +/- 2.0 micro Meter, with a slope of the concentration response curve of 2.1 +/- 0.3. Addition of 1 mM L-NAME resulted in an EC50of 14.6 +/- 0.5 micro Meter (slope 2.3 +/- 0.3), thus increasing the anesthetic effect of thiopental by 43%. Propofol administered alone showed an EC50of 1.9 +/- 0.1 micro Meter (slope 3.7 +/- 0.2), whereas in the presence of 1 mM L-NAME, the EC50was reduced by 26% to 1.4 +/- 0.1 micro Meter (slope 3.7 +/- 0.1). The EC50of ketamine was 59.7 +/- 0.7 micro Meter (slope 2.9 +/- 0.1), and it was reduced by 63% to 22.0 +/- 0.3 micro Meter (slope 3.1 +/- 0.1) with the addition of L-NAME.

Figure 1. (A) Concentration-response curve for the loss of righting reflex (LRR) in the dependence on thiopental concentration. (B) Concentration-response curve for LRR in the dependence on propofol concentration. (C) Concentration-response curve for LRR in the dependence on ketamine concentration.

Figure 1. (A) Concentration-response curve for the loss of righting reflex (LRR) in the dependence on thiopental concentration. (B) Concentration-response curve for LRR in the dependence on propofol concentration. (C) Concentration-response curve for LRR in the dependence on ketamine concentration.

The increase in anesthetic activity of the three intravenous anesthetic agents depended on the concentration of L-NAME added. In presence of a concentration of one of the anesthetic compounds sufficient to anesthetize 50% of the animals, L-NAME increased the fraction of anesthetized animals with increasing concentrations (Figure 2), resulting in an EC50of 89.2 +/- 2.4 micro Meter, 101.2 +/- 6.1 micro Meter, and 84.6 +/- 3.1 micro Meter, for thiopental, propofol, and ketamine, respectively. Slopes of the concentration-response curves ranged from 1.0 to 1.3. L-NAME administered alone did not alter the behavior of the tadpoles in a concentration range from 0.1 micro Meter to 10 mM. Adding 1 mM D-NAME did not change the EC50values of all three anesthetics (thiopental, 26.8 +/- 3.7 micro Meter; propofol, 2.0 +/- 0.4 micro Meter; ketamine, 57.2 +/- 6.3 micro Meter). In presence of 1 mM L-NAME and 10 mM L-arginine, the EC50of thiopental was 21.7 +/- 4.3 micro Meter.

Figure 2. Fitted concentration-response curves for L-NAME in the presence of half-maximal effective concentrations of thiopental, propofol, or ketamine. The origin of the y axis is normalized to 50% loss of righting reflex (normalized loss of righting reflex) in the absence of nitroG-L-arginine-methyl-ester. Data points were omitted for clarity.

Figure 2. Fitted concentration-response curves for L-NAME in the presence of half-maximal effective concentrations of thiopental, propofol, or ketamine. The origin of the y axis is normalized to 50% loss of righting reflex (normalized loss of righting reflex) in the absence of nitroG-L-arginine-methyl-ester. Data points were omitted for clarity.


The results of the present study show that treatment with the NOS inhibitor L-NAME reduces the anesthetic requirements of the intravenous anesthetics thiopental, propofol, and ketamine in a concentration-dependent manner. The enantiomer D-NAME did not change the effect of the anesthetic compounds, and adding L-arginine reversed the effect of L-NAME on the anesthetic potency of thiopental. The magnitude of the effect on the anesthetic action of the intravenous agents was similar to that determined for the volatile anesthetics halothane and isoflurane. [5,8] The decrease in the EC50of ketamine was greater than the EC sub 50 s of thiopental and propofol. When administered by itself, L-NAME did not influence the tadpole righting reflex, suggesting that inhibition of the NO pathway alone is not sufficient to induce an anesthetic state.

Anesthetic potencies were determined in tadpoles because it has been shown previously that steady-state conditions of aquatic animals with surrounding solutions are readily achieved. [15] The effects of anesthetics on tadpoles have been studied in great detail, exhibiting similarities to other vertebrate species including humans. [12,13,16,17] Because of the steady-state conditions, pharmacokinetic influences on drug actions can be excluded, although differences in binding to plasma proteins may occur. [12] However, the EC50values determined with this experimental design cannot be compared directly with plasma concentrations in humans because no anesthetic adjuncts were administered and because concentration-response curves were determined under steady-state conditions. Although this animal model has been used since the beginning of the century to measure the anesthetic effect of a compound, its limitations are the sensitivity at different points in the central nervous system that may not be mediating the anesthetic effect and the fact that measured concentrations do not necessarily bear a constant relation to the concentrations that provide clinical anesthesia.

The mechanisms by which anesthetics act are largely unknown, although advances have been made to define their actions at a molecular level. Anesthesia has been attributed to the effects of anesthetics on various cellular subsystems, including neuronal cell membranes and membrane proteins, such as receptors and ion channels, as well as second messenger systems. One of the cellular signal transduction pathways involves endothelial-derived relaxing factor, which has been identified as NO or a close derivative that releases NO. [18] After diffusion into neighboring cells, NO binds with high affinity to the heme group of the enzyme guanylyl cyclase, leading to conformational changes that increase the activity of the enzyme, resulting in increased cGMP concentrations. Nitric oxide is synthesized by a variety of tissues, including neuronal tissue of the central nervous system. High densities of NOS in the central nervous system have been demonstrated in the cerebellum, hypothalamus, midbrain, striatum, and hippocampus. [19,20] Increases in cGMP concentrations in neuronal tissues after stimulation of excitatory NMDA, glutamate, and kainate receptors are mediated by NO release. [21–23] Second messenger systems involving the NO pathway have been proposed to be of early evolutionary origin. [24] Nitric oxide synthesizing enzymes have, for example, been found in horseshoe crabs, arthropods that have remained unchanged for the past 500 million years. [25] Activity of NOS has also been shown in metamorphosing and adult X. laevis. [26]

The neurotransmitter NO has been suggested to be involved in nociception and maintenance of wakefulness, and lack of NO is supposed to result in impairments of consciousness such as heat stroke, cerebral malaria, ethanol intoxication, and opioid narcosis. [5,27,28] Inhibition of NOS reduces MAC values of halothane, indicating a role for NO in the mediation of consciousness. [5] Determination of MAC involves a painful stimulus, and thus reduction of MAC by NOS inhibitors may be caused by analgesia rather than by decreased levels of consciousness. [29] The current study defined anesthesia as loss of righting reflex in tadpoles induced by a nonpainful stimulus, and thus a distinction can be made between anesthetic and analgesic effects.

Intravenous anesthetics have been shown to exert actions at several neuronal receptor pathways. The observed decrease in anesthetic requirements by NOS inhibition may be caused by an interaction of L-NAME with a neuronal signal transduction pathway involving the NO-cGMP system. Several neuronal signal transduction pathways relevant to anesthesia have been shown to include the NO-cGMP system such as the NMDA receptor-, the muscarinic receptor-, and the alpha2-adrenoceptor-mediated pathways. [21,30,31] Although initially intravenous anesthetics have been reported to exert only minor effects on the NO-cGMP system, [32] recent data suggest a more complex view. Findings that pentobarbital, ketamine, fentanyl, or midazolam did not reduce rat brain NOS activity may be due to a lack of superoxide and hydrogen peroxide-removing enzymes in the assay mixture. [2] Galley and Webster [9] reported a decrease in the neuronal form of NOS activity after administration of intravenous anesthetics, including thiopental, ketamine, etomidate, and midazolam, when superoxide dismutase and catalase were added.

The barbiturate thiopental as well as propofol are thought to exert their anesthetic action at the gamma-aminobutyric acid receptor, the prevalent inhibitory receptor of the central nervous system. [33] Gamma-amino-butyric acid receptors have been shown to be colocalized with NOS in many areas of the central nervous system. [34] Release of gamma-aminobutyric acid and its receptor function are regulated by NO and cGMP. [35,36] Similar to inhalational anesthetics, barbiturates have been shown to suppress neuronal cGMP increases stimulated by NMDA and kainate receptors. [37] However, a study by Terasako et al. [10] showed that thiopental, in contrast to inhalational anesthetics, decreases cerebellar cGMP concentrations stimulated by administration of sodium nitroprusside, an NO donor independent of NOS, thus providing evidence for a direct action of thiopental at the guanylyl cyclase.

Cholinergic transmission is also involved in mediating the anesthetic state. [30,38] In rat brain, muscarinic receptors are localized in the same areas as NOS, and the NO-cGMP system was found to be involved in mediating the effects of muscarinic agonists. [39,40] In spinal cord tissue, acetylcholine releases NO by acting on muscarinic receptors, thus increasing peripheral cGMP levels and causing analgesic effects. [41] Antinociception mediated by muscarinic receptors has been shown to be antagonized by NOS inhibitors. [42] Thus NO-mediated analgesia cannot account for the decrease in EC50of intravenous anesthetics observed in the current study because administration of the NOS inhibitor L-NAME leads to decreasing cGMP levels. In addition, no painful stimulus is applied when the righting reflex is used as an anesthetic end point, suggesting that higher integrative neuronal processes rather than analgesic effects are involved. [43]

Ketamine is a noncompetitive inhibitor of NMDA receptors, suggesting that the NMDA receptor is involved in ketamine-mediated anesthesia. [44,45] Further, ketamine inhibits NO synthesis stimulated by NMDA- and non-NMDA-receptor-specific analogs. Based on these findings, investigators have speculated that inhibition of neuronal cGMP levels induced by NMDA receptor blockade is responsible for generating an anesthetic state. [46] However, in NOS-deficient mice, ketamine reduced the minimum alveolar concentration of isoflurane, thus indicating that ketamine acts on receptors different from the NMDA receptors or that NMDA receptors mediate their intracellular effects via pathways independent of NO release. [8]

The MAC of isoflurane in knockout mice without neuronal NOS activity was shown to be unaffected by the administration of the NOS inhibitor L-NAME, whereas in healthy mice anesthetic requirements were reduced. In addition, MAC values in NOS knockout mice were similar to those determined in healthy mice, and baseline consciousness was not affected. It has been suggested that the unaffected response to anesthetics in NOS-deficient mice can be explained by the presence of multiple pathways to maintain vital functions such as wakefulness. [47] Effective mechanisms must be postulated that compensate for a lack of NOS activity. This is further supported by findings of the effect of long-term administration of L-NAME on MAC values of halothane in rats. Although cerebellar NOS activities and cerebellar concentrations of cGMP were decreased in rats treated with L-NAME for 5 days, halothane MAC did not differ from untreated rats. [7] These findings indicate that NO is not the sole messenger for maintaining consciousness or pain perception but that multiple systems ensure a high level of redundancy. [8] This hypothesis is supported by our findings that acute administration of L-NAME in the absence of intravenous anesthetics did not cause a change in the animals' behavior. General anesthetics exert their effects simultaneously at various receptor systems in the central nervous system, which mediate their effects through several different signal transduction pathways, thus reducing redundancy. Suppression of only one of these pathways such as the NO-cGMP system in the absence of a general anesthetic is not sufficient to induce an anesthetic state.

Despite conflicting data regarding the effect of the intravenous anesthetics thiopental, propofol, and ketamine on the NO-cGMP pathway, the results of the present study clearly show that acute inhibition of NOS by L-NAME results in reduced anesthetic requirements of these compounds. Although experiments on knockout mice and long-term NOS-inhibited animals found no alterations in anesthetic requirements for volatile anesthetics, the interaction of acutely administered L-NAME and intravenous anesthetics indicates that the NO-cGMP system is involved in mediating the anesthetic effect of these compounds.

The authors thank Keith W. Miller, D.Phil., Edward Mallinckrodt Professor of Anesthesia, Departments of Anesthesia and of Biological Chemistry and Molecular Pharmacology, Massachusetts General Hospital, Harvard Medical School, Boston, Massachusetts, for his advice.


Dawson VL, Dawson TM: Nitric oxide actions in neurochemistry. Neurochem Int 1996; 29:97-110.
Tobin JR, Martin LD, Breslow MJ, Traystman RJ: Selective anesthetic inhibition of brain nitric oxide synthase. Anesthesiology 1994; 81:1264-9.
Kant GJ, Muller TW, Lenox RH, Meyerhoff JL: In vivo effects of pentobarbital and halothane anesthesia on levels of adenosine 3',5'-monophosphate and guanosine 3',5'-monophosphate in rat brain regions and pituitary. Biochem Pharmacol 1980; 29:1891-6.
Vulliemoz Y, Verosky M, Alpert M, Triner L: Effects of enflurane on cerebellar cGMP and on motor activity in the mouse. Br J Anaesth 1983; 55:79-84.
Johns RA, Moscicki JC, DiFazio CA: Nitric oxide synthase inhibitor dose-dependently and reversibly reduces the threshold for halothane anesthesia. A role for nitric oxide in mediating consciousness? Anesthesiology 1992; 77:779-84.
Adachi T, Kurata J, Nakano S, Murakawa M, Shichino T, Shirakami G, Shinomura T, Mori K: Nitric oxide synthase inhibitor does not reduce minimum alveolar concentration of halothane in rats. Anesth Analg 1994; 78:1154-7.
Adachi T, Shinomura T, Nakao S, Kurata J, Murakawa M, Shichino T, Seo N, Mori K: Chronic treatment with nitric oxide synthase (NOS) inhibitor profoundly reduces cerebellar NOS activity and cyclic guanosine monophosphate but does not modify minimum alveolar concentration. Anesth Analg 1995; 81:862-5.
Ichinose F, Huang PL, Zapol WM: Effects of targeted neuronal nitric oxide synthase gene disruption and nitro-L-arginine methylester on the threshold for isoflurane anesthesia. Anesthesiology 1995; 83:101-8.
Galley HF, Webster NR: Brain nitric oxide synthase activity is decreased by intravenous anesthetics. Anesth Analg 1996; 83:591-4.
Terasako K, Nakamura K, Miyawaki I, Toda H, Kakuyama M, Mori K: Inhibitory effects of anesthetics on cyclic guanosine monophosphate (cGMP) accumulation in rat cerebellar slices. Anesth Analg 1994; 79:921-6.
Firestone S, Firestone LL, Ferguson C, Blanck D: Staurosporine, a protein kinase c inhibitor, decreases the general anesthetic requirement in rana pipiens tadpoles. Anesth Analg 1993; 77:1026-30.
Tonner PH, Poppers DM, Miller KW: The general anesthetic potency of propofol and its dependence on hydrostatic pressure. Anesthesiology 1992; 77:926-31.
Tonner PH, Scholz J, Koch C, Schulte am Esch J: The anesthetic effect of dexmedetomidine does not adhere to the Meyer-Overton rule but is reversible by hydrostatic pressure. Anesth Analg 1997; 84:618-23.
Waud DR: On biological assays involving quantal responses. J Pharmacol Exp Ther 1972; 183:577-607.
Lipnick R, DE J, Gilforn I: Comparion of fish toxicity screening data for 55 alcohols with the quantitative structure-activity relationship predictions of minimum toxicity for nonreactive nonelectrolyte organic compounds. Environ Toxicol Chem 1985; 4:281-96.
Alifimoff J, Firestone L, Miller K: Anaesthetic potencies of primary alkanols: Implications for the molecular dimensions of the anesthetic site. Br J Pharmacol 1989; 96:9-16.
Firestone LL, Miller JC, Miller KW: Tables of Physical and Pharmacological Properties of Anesthetics. Edited by SH Roth, KW Miller. New York, Plenum, 1986, pp 455-70.
Palmer R, Ashton D, Moncada S: Vascular endothelial cells synthesize nitric oxide from L-arginine. Nature 1988; 333:664-6.
Bredt DS, Glatt CE, Hwang PM, Fotuhi M, Dawson TM, Snyder SH: Nitric oxide synthase protein and mRNA are discretely localized in neuronal populations of the mammalian CNS together with NADPH diaphorase. Neuron 1991; 7:615-24.
Garthwaite J: Glutamate, nitric oxide and cell-cell signaling in the nervous system. Trends Neurosci 1991; 14:60-7.
Garthwaite J, Charles SL, Chess-Williams R: Endothelium-derived relaxing factor release on activation of NMDA receptors suggests role as intracellular messenger in brain. Nature 1988; 336:385-8.
Garthwaite J, Southam E, Anderton M: A kainate receptor linked to nitric oxide synthesis from arginine. J Neurochem 1989; 53:952-4.
Bredt D, Snyder S: Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proc Natl Acad Sci U S A 1990; 87:682-5.
Moncada S: The 1991 Ulf von Euler lecture. Acta Physiol Scand 1992; 145:201-7.
Radomski MW, Martin JF, Moncada S: Synthesis of nitric oxide by haemocytes of the American horseshoe crab. Phil Trans R Soc London 1991; 334:129-33.
Crowe MJ, Brown TJ, Bresnahan JC, Beattie MS: Distribution of NADPH-diaphorase reactivity in the spinal cord of metamorphosing and adult Xenopus laevis. Brain Res Dev Brain Res 1995; 86:155-66.
Dzoljic M, De Vries R: Nitric oxide synthase inhibition reduces wakefulness. Neuropharmacology 1994; 33:1505-9.
Clark IA, Rockett KA, Cowden WB: Possible central role of nitric oxide in conditions clinically similar to cerebral malaria. Lancet 1992; 340:894-6.
Schroeder RA, Kuo PC: Nitric oxide: Physiology and pharmacology. Anesth Analg 1995; 81:1052-9.
Durieux ME: Muscarinic signaling in the central nervous system: recent developments and anesthetic implications. Anesthesiology 1996; 84:173-89.
Vulliemoz Y, Shen H, Virag L: Alpha-2 adrenoceptor agonists decrease cyclic guanosine 3',5'-monophosphate in the mouse brain. Anesthesiology 1996; 85:544-50.
Muldoon S, Van Dyke R, Hart J: Nitric oxide and anesthetics. Curr Opin Anaesth 1994; 7:87-90.
Tanelian DL, Kosek P, Mody I, MacIver MB: The role of the GABA sub A receptor/chloride channel complex in anesthesia. Anesthesiology 1993; 78:757-76.
Valtschanoff JG, Weinberg RJ, Rustioni A, Schmidt HHHW: Colocalization of neuronal nitric oxide synthase with GABA in rate cuneate nucleus. J Neurocyt 1995; 24:237-45.
Seilicovich A, Duvilanski BH, Pisera D, Theas S, Gimeno M, Rettori V, McCann SM: Nitric oxide inhibits hypothalamic luteinizing hormone-releasing hormone release by releasing gamma-aminobutyric acid. Proc Natl Acad Sci U S A 1995; 92:3421-4.
Segovia G, Porras A, Mora F: Effects of a nitric oxide donor on glutamate and GABA release in striatum and hippocampus of the conscious rat. Neuroreport 1994; 5:1937-40.
Morgan WW, Bermudez J, Chang X: The relative potency of pentobarbital in suppressing the kainic acid- or the N-methyl-D-aspartic acid-induced enhancement of cGMP in cerebellar cells. Eur J Pharmacol 1991; 204:335-8.
Zucker J: Central cholinergic depression reduces MAC for isoflurane in rats. Anesth Analg 1991; 72:790-5.
Mathes C, Thompson SH: The nitric oxide/cGMP pathway couples muscarinic receptors to the activation of Ca2 + influx. J Neurosci 1996; 16:1702-9.
Moro V, Badaut J, Springhetti V, Edvinsson L, Seylaz J, Lasbennes F: Regional study of the co-localization of neuronal nitric oxide synthase with muscarinic receptors in the rat cerebral cortex. Neuro-science 1995; 69:797-805.
Xu Z, Tong C, Eisenach JC: Acetylcholine stimulates the release of nitric oxide from rat spinal cord. Anesthesiology 1996; 85:107-11.
Iwamoto ET, Marion L: Pharmacologic evidence that spinal muscarinic analgesia is mediated by an L-arginine/nitric oxide/cyclic GMP cascade in rats. J Pharmacol Exp Ther 1994; 271:601-8.
Johns R: Nitric oxide, cyclic guanosine monophosphate, and the anesthetic state. Anesthesiology 1996; 85:457-9.
Thomson A, West D, Lodge D: An N-methylaspartate receptor-mediated synapse in rat cerebral cortex: A site of action of ketamine? Nature 1985; 313:479-81.
Irifune M, Shimizu T, Nomoto M, Fukuda T: Ketamine-induced anesthesia involves the N-methyl-D-aspartate receptor-channel complex in mice. Brain Res 1992; 596:1-6.
Gonzales JM, Loeb AL, Reichard PS, Irvine S: Ketamine inhibits glutamate-, N-methyl-D-aspartate-, and quisqualate-stimulated cGMP production in cultured cerebral neurons. Anesthesiology 1995; 82:205-13.
Johns RA: Nitric oxide and minimum alveolar concentration. TKO or knockout? Anesthesiology 1995; 83:6-7.